- Home
- FTHY vs ERAS Comparison
FTHY vs ERAS Comparison
Compare FTHY & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- ERAS
- Stock Information
- Founded
- FTHY 2020
- ERAS 2018
- Country
- FTHY United States
- ERAS United States
- Employees
- FTHY N/A
- ERAS N/A
- Industry
- FTHY Investment Managers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- ERAS Health Care
- Exchange
- FTHY Nasdaq
- ERAS Nasdaq
- Market Cap
- FTHY 539.8M
- ERAS 439.7M
- IPO Year
- FTHY N/A
- ERAS 2021
- Fundamental
- Price
- FTHY $13.94
- ERAS $2.86
- Analyst Decision
- FTHY
- ERAS Buy
- Analyst Count
- FTHY 0
- ERAS 6
- Target Price
- FTHY N/A
- ERAS $3.50
- AVG Volume (30 Days)
- FTHY 176.7K
- ERAS 1.3M
- Earning Date
- FTHY 01-01-0001
- ERAS 11-12-2025
- Dividend Yield
- FTHY 10.93%
- ERAS N/A
- EPS Growth
- FTHY N/A
- ERAS N/A
- EPS
- FTHY N/A
- ERAS N/A
- Revenue
- FTHY N/A
- ERAS N/A
- Revenue This Year
- FTHY N/A
- ERAS N/A
- Revenue Next Year
- FTHY N/A
- ERAS N/A
- P/E Ratio
- FTHY N/A
- ERAS N/A
- Revenue Growth
- FTHY N/A
- ERAS N/A
- 52 Week Low
- FTHY $12.66
- ERAS $1.01
- 52 Week High
- FTHY $14.74
- ERAS $3.30
- Technical
- Relative Strength Index (RSI)
- FTHY 27.72
- ERAS 69.19
- Support Level
- FTHY $14.10
- ERAS $2.21
- Resistance Level
- FTHY $14.21
- ERAS $2.90
- Average True Range (ATR)
- FTHY 0.09
- ERAS 0.20
- MACD
- FTHY -0.02
- ERAS 0.04
- Stochastic Oscillator
- FTHY 0.00
- ERAS 96.19
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.